Mutations in genes activating tyrosine kinase signaling (including c-KIT, N/KRAS, and FLT3) have been shown as the most frequent additional mutations in CBF AML that confer worse prognosis [51]. This evidence concerns the gene KIT and acute myeloid leukemia.